BACKGROUND: Treatment of @entity9 ( @entity9 ) can be complex, though many treatment options exist. Cryoablation (CA) is an interventional modality that has been used successfully in chronic @entity1109 and is one such option. OBJECTIVE: To study and evaluate the efficacy and safety of cryoablation for treatment of @entity9 . STUDY DESIGN: Retrospective evaluation. SETTING: Academic university-based @entity158 management center. METHODS: All @entity1 received local anesthetic injections for @entity9 . @entity1 with greater than or equal to 50% relief and less than 2 week duration of relief were treated with CA. RESULTS: Thirty-eight @entity1 with an average age of 49.6 years were included. Of the 38 @entity1 , 20 were treated for unilateral greater @entity9 , 10 for unilateral greater and lesser @entity9 , and 8 for bilateral greater @entity9 . There were 10 @entity1 and 28 @entity1 , with an average age of 45.2 years and 51.1 years, respectively. The average relief for all local anesthetic injections was 71.2%, 58.3% for @entity1 who reported 50 - 74% relief (Group 1) and 82.75% for @entity1 who reported greater than 75% relief (Group 2). The average improvement of @entity158 relief with CA was 57.9% with an average duration of 6.1 months overall. Group 1 reported an average of 45.2% relief for an average of 4.1 months with CA. In comparison, Group 2 reported an average of 70.5% relief for 8.1 months. The percentage of relief (P = 0.007) and duration of relief (P = 0.0006) was significantly improved in those reporting at least 75% relief of @entity158 with local anesthetic injections (Group 2 vs Group 1). Though no significance in improvement from CA was found in @entity1 , significance was seen in @entity1 with at least 75% benefit with local anesthetic injections in terms of duration (P = 0.03) and percentage (P = 0.001) of @entity158 relief with CA. The average @entity158 score prior to CA was 8 (0 - 10 visual analog scale, VAS), this improved to 4.2, improvement of 3.8 following CA at 6 months (P = 0.03). Of the 38 @entity1 , 3 (7.8%) adverse effects were seen. Two @entity1 reported post procedure @entity5013 and one was monitored for procedure-related @entity1410 . LIMITATIONS: Study limitations include the retrospective nature of the study. Additionally, only the percentage of relief, @entity158 score, and duration of relief were collected. CONCLUSIONS: CA is safe, and should be considered in @entity1 with @entity9 . KEY WORDS: Cryoablation, cryoanalgesia, @entity9 , treatment, adverse effects.

Cryoablation for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'Patients', 'patients'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['neuropathic conditions'] @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematoma'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity9 :: ('MESH:D009437', 'Disease') :: ['occipital neuralgia', 'ON'] @entity5013 :: ('MESH:D009443', 'Disease') :: ['neuritis']
@entity9 :: (MESH:D009437,Disease) :: ['occipital neuralgia']
